{"entity":{"id":"nct05269316","kind":"trial","name":"Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of IMP9064 in advanced solid tumours, run by Impact Therapeutics, Inc., now recruiting.","summary":"Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05269316 by Impact Therapeutics, Inc., with 61 participants planned, started 2022-02-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: IMP9064.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05269316","url":"https://clinicaltrials.gov/study/NCT05269316"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["impact-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05269316","phase":"1/2","setting":"A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors","sponsor":"Impact Therapeutics, Inc.","enrolled":61,"outcomes":[]},"route":"/trials/nct05269316/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/"}]}}